STOCKHOLM--(BUSINESS WIRE)--Cantargia AB’s (”Cantargia”) interim report for January – March 2016 is available on the company website (www.cantargia.com/Investors/Reports).
Significant events in the first quarter
· Approval from the European Patent Office (EPO) of Cantargia’s patent application for IL1RAP as target for antibody therapy and diagnostics of several types of solid tumours, and patent approvals in Australia, Japan and Mexico for use of IL1RAP as target molecule for antibody treatment of hematological malignancies.
Significant events in the first quarter
· Approval from the European Patent Office (EPO) of Cantargia’s patent application for IL1RAP as target for antibody therapy and diagnostics of several types of solid tumours, and patent approvals in Australia, Japan and Mexico for use of IL1RAP as target molecule for antibody treatment of hematological malignancies.
